Samsung Biologics and TG therapeutics have expanded their existing contract to manufacture Ublituximab, a monoclonal antibody drug to treat multiple sclerosis.  Korean Contract development manufacturing organization (CDMO) Samsung Biologics and US-based firm TG Therapeutics have expanded their 2018 contract to produce TG’s ublituximab (TG-1101), a monoclonal antibody (mAb) that targets an epitope on CD20-expressing B-cells. Samsung Biologics did not divulge ublituximab’s manufacturing process due to client confidentiality. However, a spokeswoman for the firm told BioProcess Insider it will “offer large-scale…

Avectas has received funding to develop a cell engineering technology platform to manufacture ‘off-the-shelf’ cell therapies for cancer treatment. Irish cell engineering firm Avectas is leading a project in partnership with the National Institute for Bioprocessing Research and Training (NIBRT) and Bluebridge Technologies, which will invest $8.7 million – including $5.3 million awarded by the Irish Government’s Disruptive Technology Innovation Fund (DTIF) – to develop the cell engineering platform Solupore. “Solupore is a comprehensive end-to-end cell engineering platform that comprises…

Novavax has switched up its leadership with multiple changes. Meanwhile there are changes at Kyverna and Precision BioSciences. Put your feet up and enjoy BioProcess Insider’s Ins & Outs. US-based biotechnology company Novavax develops and commercializes various vaccines to treat infectious diseases such as Ebola, seasonal influenza, and COVID-19. The firm has its own COVID-19 vaccine candidate, NVX-CoV2373, which has not yet received approval from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) and is currently in two Phase III…

Lonza collaborates with Immunitas to develop candidate; MedPacto signs agreement with Samsung Biologics; Revolo Biotherapeutics chooses CordenPharma to manufacture its peptide and immune system resetting drug candidate. Great to have you here for Bioprocess Insider’s CDMO round-up. First up in our contract development manufacturing organization (CDMO) round-up is Lonza, which recently entered an agreement with Immunitas Therapeutics to support manufacturing of Immunitas’ lead program, IMT-009. IMT-099 is a monoclonal antibody that suppresses NK cells and T cells in the tumor microenvironment and…

The US FDA’s CDER  has named Patrizia Cavazzoni as its permanent director. Meanwhile, there are high level changes at Rentschler Biopharma, Bone Therapeutics, and Imvax. Sit back, relax, and enjoy BioProcess Insider’s Ins & Outs. The appointment comes after Cavazzoni has served as acting director of the US Food and Drug Administration’s Center for Drug Evaluation and Research (FDA’s CDER) for the past year after Janet Woodcock stepped away from the role to assist Operation Warp Speed (OWS) in response to…